# A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

> **NCT00940485** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 200 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** entecavir
- **DRUG:** entecavir
- **DRUG:** peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT00940485
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2016-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00940485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00940485, "A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00940485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*